vs
Amneal Pharmaceuticals, Inc.（AMRX）与拜玛林制药（BMRN）财务数据对比。点击上方公司名可切换其他公司
拜玛林制药的季度营收约是Amneal Pharmaceuticals, Inc.的1.1倍（$874.6M vs $814.3M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs -5.3%，领先9.6%），拜玛林制药同比增速更快（17.0% vs 11.5%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $58.9M），过去两年拜玛林制药的营收复合增速更高（16.1% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
拜玛林制药是总部位于美国加利福尼亚州圣拉斐尔的生物技术企业，在美洲、亚洲、欧洲多地设有办事机构及生产设施，核心业务聚焦酶替代疗法研发，是全球首个推出Ⅰ型粘多糖贮积症治疗药物拉罗尼酶及苯丙酮尿症治疗药物的企业。
AMRX vs BMRN — 直观对比
营收规模更大
BMRN
是对方的1.1倍
$814.3M
营收增速更快
BMRN
高出5.6%
11.5%
净利率更高
AMRX
高出9.6%
-5.3%
自由现金流更多
AMRX
多$49.6M
$58.9M
两年增速更快
BMRN
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $874.6M |
| 净利润 | $35.1M | $-46.6M |
| 毛利率 | 36.5% | 68.5% |
| 营业利润率 | 13.8% | -5.1% |
| 净利率 | 4.3% | -5.3% |
| 营收同比 | 11.5% | 17.0% |
| 净利润同比 | 212.9% | -137.3% |
| 每股收益（稀释后） | $0.10 | $-0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXBMRN
| Q4 25 | $814.3M | $874.6M | ||
| Q3 25 | $784.5M | $776.1M | ||
| Q2 25 | $724.5M | $825.4M | ||
| Q1 25 | $695.4M | $745.1M | ||
| Q4 24 | $730.5M | $747.3M | ||
| Q3 24 | $702.5M | $745.7M | ||
| Q2 24 | $701.8M | $712.0M | ||
| Q1 24 | $659.2M | $648.8M |
净利润AMRXBMRN
| Q4 25 | $35.1M | $-46.6M | ||
| Q3 25 | $2.4M | $-30.7M | ||
| Q2 25 | $22.4M | $240.5M | ||
| Q1 25 | $12.2M | $185.7M | ||
| Q4 24 | $-31.1M | $124.9M | ||
| Q3 24 | $-156.0K | $106.1M | ||
| Q2 24 | $6.0M | $107.2M | ||
| Q1 24 | $-91.6M | $88.7M |
毛利率AMRXBMRN
| Q4 25 | 36.5% | 68.5% | ||
| Q3 25 | 34.9% | 82.0% | ||
| Q2 25 | 39.5% | 81.8% | ||
| Q1 25 | 36.8% | 79.7% | ||
| Q4 24 | 36.0% | 81.8% | ||
| Q3 24 | 38.4% | 74.7% | ||
| Q2 24 | 35.6% | 81.7% | ||
| Q1 24 | 36.1% | 80.7% |
营业利润率AMRXBMRN
| Q4 25 | 13.8% | -5.1% | ||
| Q3 25 | 9.0% | -6.0% | ||
| Q2 25 | 15.4% | 33.5% | ||
| Q1 25 | 14.4% | 30.0% | ||
| Q4 24 | 10.4% | 21.6% | ||
| Q3 24 | 12.6% | 15.3% | ||
| Q2 24 | 13.6% | 16.9% | ||
| Q1 24 | -1.6% | 13.6% |
净利率AMRXBMRN
| Q4 25 | 4.3% | -5.3% | ||
| Q3 25 | 0.3% | -4.0% | ||
| Q2 25 | 3.1% | 29.1% | ||
| Q1 25 | 1.8% | 24.9% | ||
| Q4 24 | -4.3% | 16.7% | ||
| Q3 24 | -0.0% | 14.2% | ||
| Q2 24 | 0.9% | 15.1% | ||
| Q1 24 | -13.9% | 13.7% |
每股收益（稀释后）AMRXBMRN
| Q4 25 | $0.10 | $-0.22 | ||
| Q3 25 | $0.01 | $-0.16 | ||
| Q2 25 | $0.07 | $1.23 | ||
| Q1 25 | $0.04 | $0.95 | ||
| Q4 24 | $-0.10 | $0.65 | ||
| Q3 24 | $0.00 | $0.55 | ||
| Q2 24 | $0.02 | $0.55 | ||
| Q1 24 | $-0.30 | $0.46 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $1.3B |
| 总债务越低越好 | $2.6B | — |
| 股东权益账面价值 | $-70.8M | $6.1B |
| 总资产 | $3.7B | $7.6B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AMRXBMRN
| Q4 25 | $282.0M | $1.3B | ||
| Q3 25 | $201.2M | $1.3B | ||
| Q2 25 | $71.5M | $1.2B | ||
| Q1 25 | $59.2M | $1.0B | ||
| Q4 24 | $110.6M | $942.8M | ||
| Q3 24 | $74.0M | $675.4M | ||
| Q2 24 | $43.8M | $972.1M | ||
| Q1 24 | $46.5M | $747.0M |
总债务AMRXBMRN
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
股东权益AMRXBMRN
| Q4 25 | $-70.8M | $6.1B | ||
| Q3 25 | $-109.5M | $6.1B | ||
| Q2 25 | $-112.1M | $6.0B | ||
| Q1 25 | $-131.7M | $5.8B | ||
| Q4 24 | $-109.3M | $5.7B | ||
| Q3 24 | $-93.4M | $5.4B | ||
| Q2 24 | $-57.5M | $5.3B | ||
| Q1 24 | $-63.7M | $5.1B |
总资产AMRXBMRN
| Q4 25 | $3.7B | $7.6B | ||
| Q3 25 | $3.6B | $7.6B | ||
| Q2 25 | $3.4B | $7.5B | ||
| Q1 25 | $3.4B | $7.1B | ||
| Q4 24 | $3.5B | $7.0B | ||
| Q3 24 | $3.5B | $6.9B | ||
| Q2 24 | $3.5B | $7.1B | ||
| Q1 24 | $3.5B | $6.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $99.6M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $58.9M |
| 自由现金流率自由现金流/营收 | 13.3% | 6.7% |
| 资本支出强度资本支出/营收 | 2.7% | 4.7% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $725.0M |
8季度趋势，按日历期对齐
经营现金流AMRXBMRN
| Q4 25 | $130.3M | $99.6M | ||
| Q3 25 | $118.5M | $368.7M | ||
| Q2 25 | $83.8M | $185.3M | ||
| Q1 25 | $7.4M | $174.4M | ||
| Q4 24 | $118.1M | $185.6M | ||
| Q3 24 | $141.8M | $221.5M | ||
| Q2 24 | $39.7M | $118.8M | ||
| Q1 24 | $-4.4M | $47.0M |
自由现金流AMRXBMRN
| Q4 25 | $108.5M | $58.9M | ||
| Q3 25 | $106.2M | $340.2M | ||
| Q2 25 | $61.0M | $168.2M | ||
| Q1 25 | $-5.8M | $157.6M | ||
| Q4 24 | $102.9M | $166.1M | ||
| Q3 24 | $124.8M | $203.0M | ||
| Q2 24 | $29.0M | $97.4M | ||
| Q1 24 | $-13.6M | $20.9M |
自由现金流率AMRXBMRN
| Q4 25 | 13.3% | 6.7% | ||
| Q3 25 | 13.5% | 43.8% | ||
| Q2 25 | 8.4% | 20.4% | ||
| Q1 25 | -0.8% | 21.2% | ||
| Q4 24 | 14.1% | 22.2% | ||
| Q3 24 | 17.8% | 27.2% | ||
| Q2 24 | 4.1% | 13.7% | ||
| Q1 24 | -2.1% | 3.2% |
资本支出强度AMRXBMRN
| Q4 25 | 2.7% | 4.7% | ||
| Q3 25 | 1.6% | 3.7% | ||
| Q2 25 | 3.2% | 2.1% | ||
| Q1 25 | 1.9% | 2.3% | ||
| Q4 24 | 2.1% | 2.6% | ||
| Q3 24 | 2.4% | 2.5% | ||
| Q2 24 | 1.5% | 3.0% | ||
| Q1 24 | 1.4% | 4.0% |
现金转化率AMRXBMRN
| Q4 25 | 3.72× | — | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | 0.77× | ||
| Q1 25 | 0.61× | 0.94× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 2.09× | ||
| Q2 24 | 6.62× | 1.11× | ||
| Q1 24 | — | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
